Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab in Sjögren's Syndrome
NCT02614716Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Sep 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in Sjögren's syndrome comparing LY3090106 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Dec 2015; status: completed.
02
Drugs
tibulizumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT02614716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614716.